title: Chronic Cholestatic Liver Injury Attributable to Vedolizumab.
abstract: Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.
authors: Division of Gastroenterology & Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
authors: Jonathan G
authors: JG
authors: Stine
authors: Department of Medicine, University of Virginia, Charlottesville, VA, USA.
authors: Jennifer
authors: J
authors: Wang
authors: Division of Gastroenterology & Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
authors: Brian W
authors: BW
authors: Behm
keywords: Hepatotoxicity; Inflammatory bowel disease; Integrin inhibitor; Primary sclerosing cholangitis